ArticleBiological trace element research2025
Therapeutic Potential of Green Synthesized Polyherbal Formulated Silver Nanoparticles in Alloxan-Induced Diabetes Mellitus-An In Vivo Strategy.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant-Mediated Silver Nanoparticle Formulations for Wound Healing: A Process-Property-Performance Perspective.Pharmaceutics · 2026Review
- Advanced Bioinspired Silver Nanoparticles Integrated into Polyherbal Gel for Enhanced Diabetic Foot Ulcer Regeneration.Biological trace element research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a non-communicable, life-threatening syndrome prevalent worldwide. One effective treatment for DM is the medicinal use of green synthesized silver nanoparticles (AgNPs), which are eco-friendly and cost-effective. This study investigates the antidiabetic potential of greensynthesizedAgNPs derived from a polyherbal formulation (PHF). Characterization of PHF-AgNPs included UV-Vis spectroscopy, FTIR, XRD, SEM, and EDX. Diabetes was induced in albino Wistar rats (N = 30, n = 6/group, 150-200 g, 8 weeks old) via intraperitoneal alloxan injection (150 mg). Groups are as follows: 1) untreated control, 2) diabetic control (150 mg/kg b.w. alloxan), 3) glibenclamide (0.5 mg/kg), 4) PHF-AgNPs (10 mg/kg), and 5) PHF-AgNPs (20 mg/kg). Blood glucose levels (BGL) were monitored on days 0, 7, 14, and 21. Blood samples were collected for the liver, kidney, and lipid profile analysis before euthanization. The results showed that PHF-AgNPs had an average size of 20 nm and exhibited significant reductions in BGL, with PHF-AgNPs at both 10 mg/kg and 20 mg/kg demonstrating superior effects compared to glibenclamide. Histopathological analysis revealed tissue regeneration in the liver, kidney, and pancreas, indicating healing of alloxan-induced damage. Additionally, treatment improved liver and kidney function markers, and lipid profiles, with reductions in cholesterol, triglycerides, ALT, AST, and creatinine levels compared to the diabetic control group. These findings suggest that green synthesized PHF-AgNPs effectively improved blood glucose control, body weight, and organ health, positioning them as a promising antidiabetic agent with potential for further clinical development.
Indexed as
Identifiers
40075015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.